Neupogen (Filgrastim)

Filgrastim mimics the natural granulocyte colony‑stimulating factor by binding to the G‑CSF receptor on bone‑marrow progenitor cells. This activates signaling pathways that stimulate proliferation, differentiation, and activation of neutrophil precursors, leading to increased production and release of mature neutrophils into the bloodstream.

The dose of Neupogen is individualized and must be prescribed by a qualified healthcare professional. The prescriber determines the appropriate amount, frequency, and route of administration based on the patient’s clinical condition, treatment setting, and response to therapy.

The safety of filgrastim in pregnancy and lactation has not been definitively established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by the treating physician in consultation with the patient.

To order Neupogen, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, cold‑chain shipping details, and import documentation.

The primary alternative to filgrastim is pegfilgrastim, a pegylated, long‑acting form that requires a single injection per chemotherapy cycle. Filgrastim has a shorter half‑life and may be administered daily, offering flexibility in dosing schedules, whereas pegfilgrastim provides convenience with fewer injections but at a higher cost.

Neupogen must be stored refrigerated at 2‑8 °C (36‑46 °F). Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. If the product reaches room temperature, it may be used within the time frame specified in the labeling, after which any remaining solution should be discarded.

Neupogen is supplied as an injectable solution for intravenous or subcutaneous injection. Administration is performed by a qualified healthcare professional in a clinical setting, following aseptic technique and the dosing instructions provided by the prescriber.

Serious adverse events include splenic rupture, acute respiratory distress syndrome (ARDS), and severe allergic reactions such as anaphylaxis. Patients should be monitored for signs of abdominal pain, respiratory difficulty, or any rapid onset of rash or swelling, and treatment should be discontinued if these events occur.

Neupogen is contraindicated in individuals with a known hypersensitivity to filgrastim or any of its excipients. Caution is also advised for patients with active, uncontrolled infections, severe splenomegaly, or those who have experienced severe adverse reactions to G‑CSF therapy in the past.